Shares of XBiotech Inc. (NASDAQ:XBIT) were down 2.7% on Monday . The company traded as low as $14.45 and last traded at $14.54, with a volume of 108,155 shares changing hands. The stock had previously closed at $14.95.

A number of analysts have recently weighed in on XBIT shares. Noble Financial restated a “buy” rating and issued a $30.00 target price (up from $24.00) on shares of XBiotech in a research note on Tuesday, June 28th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Tuesday, April 5th.

The firm’s market capitalization is $500.78 million. The firm’s 50 day moving average price is $17.17 and its 200 day moving average price is $11.91.

In other news, Director W Thorpe Mckenzie acquired 20,000 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were purchased at an average cost of $13.96 per share, with a total value of $279,200.00. Following the acquisition, the director now directly owns 3,898,600 shares in the company, valued at approximately $54,424,456. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.